Trade

with

Pain Therapeutics Inc
(NASDAQ: PTIE)
AdChoices
4.17
+0.06
+1.46%
After Hours :
-
-
-

Open

4.13

Previous Close

4.11

Volume (Avg)

5.00k (178.13k)

Day's Range

4.13-4.17

52Wk Range

3.40-6.22

Market Cap.

188.06M

Dividend Rate ( Yield )

-

Beta

1.09

Shares Outstanding

45.76M

P/E Ratio (EPS)

7.29 (0.56)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 41.12M

    • Net Income

    • 31.54M

    • Market Cap.

    • 188.06M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 68.70

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.09

    • Forward P/E

    • -10.28

    • Price/Sales

    • 5.01

    • Price/Book Value

    • 4.31

    • Price/Cash flow

    • -22.17

      • EBITDA

      • 31.36M

      • Return on Capital %

      • 51.85

      • Return on Equity %

      • 88.39

      • Return on Assets %

      • 51.85

      • Book Value/Share

      • 0.95

      • Shares Outstanding

      • 45.76M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.40

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 1,328.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -8.39

          • 63.43

          • Net Income

            5-Year Annual Average

          • 15.50

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • 68.50

            • 39.38

            • Net Profit Margin

            • 68.70

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -14.70

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -13.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 26.05

              • 2.92

              • Quick Ratio

              • 25.78

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.04

              • 2.21

              • Book Value/Share

              • 0.95

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 7.45

                • 243.90

                • P/E Ratio 5-Year High

                • 18.53

                • 634.30

                • P/E Ratio 5-Year Low

                • 3.81

                • 124.82

                • Price/Sales Ratio

                • 5.12

                • 9.29

                • Price/Book Value

                • 4.40

                • 8.39

                • Price/Cash Flow Ratio

                • -22.17

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 88.39

                    (12.70)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 51.85

                    (8.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 88.39

                    (12.70)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 3.19M

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.75

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  31.36M
                  Operating Margin
                  76.28
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -22.17
                  Ownership

                  Institutional Ownership

                  59.99%

                  Top 10 Institutions

                  40.19%

                  Mutual Fund Ownership

                  12.40%

                  Float

                  83.41%

                  5% / Insider Ownership

                  11.68%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    648,431

                  • 0.00

                  • 1.42

                  • iShares Russell 2000 (AU)

                  •  

                    570,038

                  • -1.81

                  • 1.31

                  • Vanguard Extended Market Index Fund

                  •  

                    459,455

                  • 1.12

                  • 1.00

                  • Vanguard US Discoveries Fund

                  •  

                    370,680

                  • -2.32

                  • 0.81

                  • iShares Russell 2000 Growth

                  •  

                    261,032

                  • -1.57

                  • 0.60

                  • Bridgeway Ultra Small Company Market

                  •  

                    216,853

                  • 0.00

                  • 0.48

                  • Gabelli Small Cap Growth Fund

                  •  

                    215,000

                  • -6.52

                  • 0.47

                  • DFA U.S. Small Cap Portfolio

                  •  

                    199,360

                  • 4.48

                  • 0.44

                  • DFA U.S. Micro Cap Portfolio

                  •  

                    179,167

                  • 0.00

                  • 0.39

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Arnhold & S. Bleichroeder Advisers, LLC

                  •  

                    4,474,735

                  • +22.14%

                  • 9.81

                  • Visium Asset Management LLC

                  •  

                    4,350,000

                  • 0.00%

                  • 9.54

                  • Madison Street Partners, LLC

                  •  

                    1,876,201

                  • +9.86%

                  • 4.10

                  • Great Point Partners LLC

                  •  

                    1,694,256

                  • -25.93%

                  • 3.72

                  • BlackRock Fund Advisors

                  •  

                    1,506,367

                  • +2.95%

                  • 3.30

                  • Vanguard Group, Inc.

                  •  

                    1,237,370

                  • +6.41%

                  • 2.71

                  • Sophrosyne Capital LLC

                  •  

                    951,362

                  • +1.24%

                  • 2.09

                  • Dimensional Fund Advisors, Inc.

                  •  

                    761,998

                  • +24.02%

                  • 1.67

                  • Acadian Asset Management LLC

                  •  

                    760,158

                  • +16.37%

                  • 1.66

                  • Burlingame Asset Management LLC

                  •  

                    721,922

                  • -83.57%

                  • 1.59

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Pain Therapeutics, Inc., a Delaware corporation was incorporated in May 1998. The Company is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including REMOXY, PTI-202,...more PTI-721 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Its drug candidate is called REMOXY. REMOXY is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use. REMOXY is a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. The Company owns all commercial rights to its pipeline of drug candidates in oncology and hematology. It relies on a limited number of third-party manufacturers to formulate, manufacture, fill, label, ship ...moreor store all of its drug candidates. The company’s strategies include Focus on Clinical Development Stage Products. It believes this focus will enable the company to generate product revenues earlier than if it was focused on early-stage research and discovery activities; Retain Significant Rights to Drugs: It currently retain worldwide commercialization rights to all of its technology and drug candidates in all markets and indications, except for REMOXY and certain other abuse-resistant drugs. The Company has an exclusive, worldwide Development and License Agreement, or the Durect Agreement, with Durect Corporation, or Durect, to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Companies that currently sell generic or proprietary opioid formulations include, but are not limited to, Roxane Laboratories, Purdue Pharma, Pfizer, Abbott Laboratories, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.lessless

                  Key People

                  Remi Barbier

                  CEO/Chairman of the Board/Director/Founder/President

                  Peter S. Roddy

                  CFO/Chief Accounting Officer/Vice President

                  Dr. Patrick J. Scannon,M.D.,PhD

                  Director

                  Nadav Friedmann,M.D.

                  Chief Medical Officer/COO/Director

                  Sanford R. Robertson

                  Director

                  • Pain Therapeutics Inc

                  • 7801 N. Capital of Texas Highway

                  • Austin, TX 78731

                  • USA.Map

                  • Phone: +1 512 501-2444

                  • Fax: +1 650 624-8222

                  • paintrials.com

                  Incorporated

                  1998

                  Employees

                  8

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: